Ronnie Andrews joined Oncocyte as Chief Executive Officer in July 2019. Before joining Oncocyte, Ronnie was the founder and principal of the Bethesda Group LLC; a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms into the marketplace.
Ronnie has close to 30 years of experience in the US Clinical and Molecular Diagnostics industry. He served as the President of the Genetic Science Division for Thermo Fisher Scientific until December 2014. In this role, Ronnie oversaw the integration of Life Technologies’ genetic platforms, including Life’s chip-based Next Generation Sequencing Technology, Ion Torrent.
Before this, Ronnie held several other high-profile executive roles, including President of the Medical Sciences Venture within the Life Technologies Corporation, and he served as Chief Executive Officer of Clarient, a public company on the NASDAQ, which was sold to General Electric Healthcare in December 2010.
Ronnie is a passionate ambassador for the need for democratization of information into community-based environments to better manage deadly diseases like cancer, as well as control healthcare costs by keeping the patient and treatment close to home. He regularly speaks to industry groups and was selected as the Regional Winner for Ernst & Young’s Entrepreneur of the Year in 2011.
Al Parker joined Oncocyte as Chief Operating Officer in August 2018. Mr. Parker is an accomplished business and legal executive with over 25 years of broad domestic and international life sciences experience, having served in executive leadership roles in leading pharmaceutical, biotech, and healthcare companies.
With a background in strategic planning, business development, and operations, Mr. Parker’s prior roles include Executive Vice President, General Counsel and Corporate Secretary for Sunovion Pharmaceuticals, Senior Vice President and Global Chief Counsel for Wyeth Pharmaceuticals, and Managing Shareholder at GC Legal Advisors, where he also served in interim chief legal and compliance officer and other operating roles at several early-stage biotechs, pharma, and other healthcare-related companies.
Committed to strong corporate governance, Mr. Parker has been recognized as a Board Governance Fellow by the National Association of Corporate Directors. Mr. Parker earned his Juris Doctor from the University of Pennsylvania Law School and his undergraduate degree in Economics from Penn State University.
Padma Sundar has extensive experience in launching oncology tests for global diagnostics companies, helping them achieve market leadership positions.
Before joining Oncocyte, Ms. Sundar served as Vice President of Strategy and Market Access at CellMax Life, where she launched the first blood test for preventative colon cancer screening. Before CellMax, she was a Director of Marketing at Guardant Health, where she drove a 75% increase in test volume and adoption by U.S. oncologists.
As a Senior Director at Roche Sequencing, she launched the first next-generation sequencing (NGS) liquid biopsy kit for cancer recurrence monitoring. She was also Senior Director for the oncology portfolio at Affymetrix, where she brought the first whole-genome microarray kits “OncoScan” and “CytoScan” for solid and liquid tumor profiling to 50 leading academic and reference labs worldwide.
Ms. Sundar began her career at McKinsey and Company. She received her M.B.A. and M.P.H. from the University of California, Berkeley, and her B.A. in Chemistry from the University of Delhi.
Lyndal Hesterberg Ph.D., joined Oncocyte as a consultant in 2015 and was named Vice President of Development in February of 2016.
Dr. Hesterberg has worked as an industry consultant to medical and biotech companies providing counsel on clinical trial design, product development, and corporate strategy. Previously, he was the CTO at Crescendo Biosciences until 2012, where he was responsible for the clinical trial, laboratory operations, manufacturing, and quality systems and helped bring to market Vectra DA.
Before that, he was the president and CEO of Barofold, Inc., where he led the Company from product conception through its clinical stage. He also recruited a senior leadership team that developed a pipeline of proprietary drug candidates.
Dr. Hesterberg also has been a Director of Research, EVP of Scientific affairs, and Manager of Diagnostic Product Development. He received his Ph.D. in biochemistry from the University of St. Louis and a Bachelor of Sciences from the University of Illinois.
Lyndal Hesterberg, Ph.D.
Chief Scientific Officer
View more >>
Prior to joining Oncocyte, Dr. Doug Ross was a founding principal in the Bethesda Group, LLC, a boutique consulting firm that provided technical, commercial and operational expertise to the diagnostic and pharma industry. He is an experienced medical diagnostics R&D executive with a background in research and development at the intersections between genomics, proteomics and diagnostics. He co-founded a successful genomics-based diagnostic business, served in executive leadership positions in CLIA reference laboratories, and managed proprietary content through research, development and launch.
Doug’s private sector career started in 2000 as Chief Scientific Officer of Applied Genomics, Inc. (AGI), a company he co-founded coming out of post-doctoral training at Stanford University. AGI translated insights from gene expression patterns into immunohistochemistry multivariate assays targeted to actionable clinical problems.
In 2009, Clarient, Inc., a leading national pathology reference laboratory, acquired AGI. Doug continued his role as Chief Scientific Officer and launched two proprietary products. General Electric Healthcare acquired Clarient in December 2010, and Doug continued as CSO and worked closely with the business development and partnership teams at Clarient and capital teams at GE Healthcare.
In 2011 Doug joined the Medical Science Division of Life Technologies as CSO on a consulting basis until the acquisition of Life Tech by Thermo Fisher Scientific in 2013. He was CSO of CardioDx, Inc. from April to December of 2014. In September 2015, Doug became a founding principal in Bethesda Group, LLC.
Doug obtained his M.D. and his Ph.D. in Pathology from the University of Washington while studying at the Fred Hutchinson Cancer Research Center in Seattle, WA. He completed two years of Clinical Pathology training including serving as Chief Resident at the University of California at San Francisco before joining the genomics project as a post-doc with Patrick Brown at Stanford University in 1996.
Doug Ross, M.D., Ph.D.
Chief Scientific Officer
View more >>
Dr. Dickinson has over two decades of industry expertise in overseeing global clinical trials and diagnostic testing, with an emphasis on anatomic, clinical, and digital pathology.
Before joining Oncocyte, Dr. Dickinson served as Vice President of R&D and Chief Pathologist at BioCare Medical, where she led a team responsible for the R&D and testing of antibody optimizations to support the launch and release of a new immunohistochemistry instrument. Before BioCare, she was a Vice President of Clinical Operations at Roche Tissue Diagnostics, where she provided strategic, operational leadership supporting the coordination and execution of more than 100 companion diagnostic, in vitro diagnostic clinical trials.
Previously, at Laboratory Corporation of America, she was the Medical Director for the Clinical Trials Division, where she directed daily operations across five global anatomic pathology lab testing sites, as well as Medical Director for Esoteric Testing, where she led a team of pathologists and operations staff.
She received her M.D. from Hahnemann University, her M.B.A. and M.P.H. from the University of California, Irvine, and her B.Sc. in Pharmacy from the University of Pittsburgh.
Dr. Kim Dickinson
Vice President, Clinical Operations
View more >>
Dr. Johannes Kratz is the Director of Minimally Invasive and Robotic Thoracic Surgery and Van Auken Endowed Chair in Thoracic Oncology at the University of California, San Francisco (UCSF).
Dr. Kratz played a pivotal role in the development of the DetermaRx test during his time working with David M. Jablons, M.D. and Michael Mann, M.D. as a research fellow in the Thoracic Oncology Lab at UCSF, and is now a Principal Investigator researching the genetic and immunological mechanisms that drive early-stage lung cancer. His work has been published in leading medical journals including the Lancet, JAMA, and the Journal of Thoracic Oncology.
Dr. Kratz has been the recipient of numerous awards and honors including the Partners Healthcare Resident/Fellow as Teacher Award, Willard M. Daggett Award, Edward Churchill Surgical Research Fellowship, Wyeth Scholarship of the American College of Surgeons, John E. Thayer Scholarship Award, Howard Hughes Medical Fellows Program Continued Support Award, Howard Hughes Medical Student Research Fellowship, and designation as a Soma Weiss Scholar.
He graduated magna cum laude from Harvard Medical School and holds a Masters in Philosophy from Stanford.
Johannes R. Kratz, M.D., FACP
Assistant Professor of Surgery Division of Adult Cardiothoracic Surgery Van Auken Endowed Chair in Thoracic Oncology Director, Minimally Invasive and Robotic Thoracic Surgery Associate Director, Thoracic Surgery Residency Program
View more >>